Identification of circRNA-miRNA-mRNA regulatory network and its role in cardiac hypertrophy

Ke Gong1, Kai Yang2, Ting Xie1

  • 1Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Central South University, Changsha, P.R. China.

Plos One
|March 23, 2023
PubMed

Insights

This study identifies a novel circRNA-miRNA-mRNA network involved in hypertrophic cardiomyopathy (HCM). This network may offer new biomarkers for early screening and predicting prognosis of HCM.

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) poses a significant health risk.
  • Circular RNAs (circRNAs) and microRNAs (miRNAs) are key players in HCM.
  • The role of ceRNA networks in HCM requires further investigation.

Purpose of the Study:

  • To investigate the biological activities of ceRNA in HCM.
  • To construct a ceRNA network for HCM.
  • To identify potential biomarkers and therapeutic targets for HCM.

Main Methods:

  • Analyzed Gene Expression Omnibus (GEO) database for differentially expressed RNAs in HCM.
  • Predicted circRNA and miRNA targets.
  • Constructed a circRNA-miRNA-mRNA ceRNA network.
  • Performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
  • Validated hub genes using quantitative polymerase chain reaction (qPCR).

Main Results:

  • Identified a ceRNA network with two differentially expressed circRNAs, two differentially expressed miRNAs, and thirty differentially expressed mRNAs.
  • Pathway analysis linked HCM mechanisms to calcium channel release.
  • qPCR confirmed differential expression of circRNA, miRNA, and mRNA.

Conclusions:

  • A circRNA-miRNA-mRNA network is closely related to HCM progression and outcomes.
  • This network may provide novel noninvasive biomarkers for early screening and prognostic prediction of HCM.
  • The identified network holds potential as a source of therapeutic targets for HCM.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
14
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19